Heinemann V, von Weikersthal LF, Decker T et al (2014) Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075. https://doi.org/10.1016/s1470-2045(14)70330-4

Article  CAS  PubMed  Google Scholar 

Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392–2401. https://doi.org/10.1001/jama.2017.7105

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271–1282. https://doi.org/10.1001/jama.2023.4428

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214. https://doi.org/10.1200/JCO.2004.11.037

Article  CAS  PubMed  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/s0140-6736(12)61900-x

Article  CAS  PubMed  Google Scholar 

Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Eng J Med 372:1909–1919. https://doi.org/10.1056/nejmoa1414325

Article  Google Scholar 

Emura T, Nakagawa F, Fujioka A et al (2004) An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13:249–255

CAS  PubMed  Google Scholar 

Murakami Y, Kazuno H, Emura T et al (2000) Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 17:277–283. https://doi.org/10.3892/ijo.17.2.277

Article  CAS  PubMed  Google Scholar 

Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319–2326. https://doi.org/10.3892/or.2014.3487

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukushima M, Suzuki N, Emura T et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2’-deoxyribonucleosides. Biochem Pharmacol 59:1227–1236. https://doi.org/10.1016/s0006-2952(00)00253-7

Article  CAS  PubMed  Google Scholar 

Emura T, Suzuki N, Yamaguchi M et al (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25:571–578

CAS  PubMed  Google Scholar 

Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Eng J Med 388:1657–1667. https://doi.org/10.1056/NEJMoa2214963

Article  CAS  Google Scholar 

Satake H, Yamazaki K, Suwa Y et al (2024) First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS). J Clin Oncol 42(3_suppl):118. https://doi.org/10.1200/JCO.2024.42.3_suppl.118

Article  Google Scholar 

Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70. https://doi.org/10.1093/annonc/mdx738

Article  CAS  PubMed  Google Scholar 

Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42. https://doi.org/10.1007/s10147-019-01485-z

Article  PubMed  Google Scholar 

Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328–335. https://doi.org/10.1016/j.bbrc.2005.05.132

Article  CAS  PubMed  Google Scholar 

Osumi H, Shinozaki E, Ooki A et al (2021) Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer Med 10:615–625. https://doi.org/10.1002/cam4.3638

Article  CAS  PubMed  Google Scholar 

Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081

Article  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE), version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 20 April 2024

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244

Article  CAS  PubMed  Google Scholar 

Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37. https://doi.org/10.1016/s1470-2045(12)70477-1

Article  CAS  PubMed  Google Scholar 

Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621. https://doi.org/10.1172/jci24612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffioen AW, Mans LA, de Graaf AMA et al (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18:3961–3971. https://doi.org/10.1158/1078-0432.ccr-12-0002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dasari A, Lonardi S, Garcia-Carbonero R et al (2023) Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402:41–53. https://doi.org/10.1016/s0140-6736(23)00772-9

Article  CAS  PubMed  Google Scholar 

Bazarbashi S, Alkhatib R, Aseafan M et al (2024) Efficacy of chemotherapy rechallenge versus regorafenib or trifluridine/tipiracil in third-line setting of metastatic colorectal cancer: a multicenter retrospective comparative study. JCO Glob Oncol 10:e2300461. https://doi.org/10.1200/go.23.00461

Article  PubMed  PubMed Central  Google Scholar 

Sartore-Bianchi A, Pietrantonio F, Lonardi S et al (2022) Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 28:1612–1618. https://doi.org/10.1038/s41591-022-01886-0